title: Lansoprazole increases serum IgG and IgM in H. pylori-infected patients.
abstract: Proton-pump inhibitors have been reported to influence the human immune system, we therefore evaluated the effect of lansoprazole, a proton-pump inhibitor, on humoral immunity. Patients with gastric ulcer received lansoprazole 30 mg/day for 8 weeks, and serum immunoglobulins were evaluated before and upon completion of the treatment. There were 79 patients with gastric ulcer; 51 were H. pylori-infected and 28 were H. pylori-uninfected. Eighteen patients positive for H. pylori were receiving at least one non-steroidal anti-inflammatory drug, and 12 patients negative for H. pylori received one non-steroidal anti-inflammatory drug. H. pylori-infected patients showed significant increases in serum immunoglobulins G and M 8 weeks after the start of lansoprazole treatment (P<0.001 for IgG and P<0.01 for IgM), but uninfected patients did not. Even when H. pylori-infected patients receiving a non-steroidal anti-inflammatory drug or low-dose aspirin were analyzed separately, these increases were seen (P<0.001 for IgG and P<0.005 for IgM). Lansoprazole elevated serum levels of immunoglobulins G and M in gastric ulcer patients with H. pylori infection, particularly in those receiving non-steroidal anti-inflammatory drugs. Deducing from these observations, lansoprazole might alter the Th1 shift in the immune response induced by H. pylori infection.
authors.affiliation: Division of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan. m-200@mbk.ocn.ne.jp
authors.forename: Y
authors.initials: Y
authors.lastname: Matsukawa
authors.forename: H
authors.initials: H
authors.lastname: Kurosaka
authors.forename: K
authors.initials: K
authors.lastname: Kato
authors.forename: I
authors.initials: I
authors.lastname: Hayashi
authors.forename: K
authors.initials: K
authors.lastname: Minekawa
authors.forename: Y
authors.initials: Y
authors.lastname: Arakawa
authors.forename: S
authors.initials: S
authors.lastname: Sawada
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000009:adverse effects* / Q000627:therapeutic use; D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology; D000917:Antibody Formation / Q000187:drug effects*; D001241:Aspirin / Q000494:pharmacology; D004347:Drug Interactions; D004791:Enzyme Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D016481:Helicobacter Infections / Q000097:blood / Q000188:drug therapy / Q000276:immunology*; D016480:Helicobacter pylori; D006801:Humans; D007070:Immunoglobulin A / Q000097:blood; D007074:Immunoglobulin G / Q000097:blood*; D007075:Immunoglobulin M / Q000097:blood*; D064747:Lansoprazole; D008297:Male; D008875:Middle Aged; D054328:Proton Pump Inhibitors; D013276:Stomach Ulcer / Q000188:drug therapy / Q000276:immunology / Q000382:microbiology
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000894:Anti-Inflammatory Agents, Non-Steroidal; D004791:Enzyme Inhibitors; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D054328:Proton Pump Inhibitors; D064747:Lansoprazole; D001241:Aspirin